Delcath Systems (DCTH) Financials

Delcath Systems’ latest quarterly results show a company that is growing revenue quickly and generating positive operating cash flow, but still posting net losses and using a meaningful amount of cash on financing and investing activities. Over the last several years, the big story has been a sharp turnaround in sales, a much stronger liquidity position, and a business that appears to be moving closer to operating breakeven, even though profitability is still inconsistent.

On the top line, Delcath’s progress has been impressive. Q1 2026 revenue was $25.0 million, up from $20.7 million in Q4 2025, $20.6 million in Q3 2025, and well above the low single-digit revenue levels seen in 2023. That suggests the company has built a much larger commercial base than it had a year or two ago.

Gross profit also remains solid. In Q1 2026, gross profit was $21.3 million on $25.0 million of revenue, implying a gross margin of roughly 85%. That’s a strong gross margin profile for a small-cap biotech/medtech company and gives Delcath more room to absorb operating expenses as revenue scales.

Operating performance is improving, but not yet consistently profitable. Q1 2026 operating loss was $1.6 million, an improvement from a $2.2 million operating loss in Q4 2025 and a much better result than the large losses seen in 2024 and early 2023. Still, the company reported a net loss of $1.07 million in Q1 2026, so the bottom line has not fully turned the corner.

Cash generation from operations is a key positive. Delcath produced $857,000 of operating cash flow in Q1 2026, after $8.2 million in Q4 2025 and $4.8 million in Q3 2025. That’s a big improvement versus the deep operating cash outflows seen in 2024 and early 2023, and it suggests the business is increasingly able to fund itself from operations.

The balance sheet is much stronger than it was a year ago. As of March 31, 2026, Delcath held $41.3 million in cash and equivalents and $48.0 million in short-term investments, for total cash-like resources of about $89.3 million. That is a major improvement from March 31, 2025, when cash and short-term investments totaled about $58.9 million.

Liquidity looks comfortable for now. Current assets were $120.3 million versus current liabilities of $10.7 million in Q1 2026. That leaves the company with a very large working-capital cushion, which is important for a small company still refining its profitability profile.

There are still several signs of risk and inconsistency. The company’s financing cash flow was negative $2.38 million in Q1 2026, mainly because it repurchased $3.0 million of common equity. That’s not necessarily bad, but it does show capital allocation is still active and somewhat volatile.

Quarter-to-quarter earnings have been choppy over the past year. Delcath swung from a net loss of $11.1 million in Q1 2024 to a loss of $1.9 million in Q4 2025, then to a loss of $1.1 million in Q1 2026. The trend is clearly better, but the business still isn’t producing stable, predictable profits.

• Revenue has climbed meaningfully over the last four quarters, reaching $25.0 million in Q1 2026 from just $3.1 million in Q1 2024, showing strong commercial momentum.
• Gross margin remains very strong, with Q1 2026 gross profit of $21.3 million on $25.0 million of revenue.
• Operating cash flow turned positive in Q1 2026, indicating the core business is generating cash.
• Liquidity is solid, with about $89.3 million in cash and short-term investments at the end of Q1 2026.
• Current assets far exceed current liabilities, giving Delcath plenty of short-term financial flexibility.
• Research and development spending remains significant, at $9.8 million in Q1 2026, which supports growth but also keeps expenses elevated.
• Share count has been relatively stable recently, though the company has had periods of dilution and equity issuance in prior quarters.
• The company is still reporting net losses, including a $1.07 million loss in Q1 2026.
• Financing cash flow was negative in Q1 2026, largely due to a $3.0 million share repurchase.
• Profitability has been volatile historically, with large losses in earlier periods and only recent signs of steady improvement.

Bottom line: Delcath Systems looks meaningfully improved versus its 2023-2024 profile. Revenue growth, strong gross margins, positive operating cash flow, and a large cash balance are all encouraging. The main question for investors is whether the company can convert that revenue growth into consistent net profitability before the recent momentum slows.